{
    "clinical_study": {
        "@rank": "127900", 
        "acronym": "DUAL\u2122", 
        "arm_group": [
            {
                "arm_group_label": "Insulin degludec/liraglutide + Metformin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin degludec/liraglutide + Insulin Aspart + Metformin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted globally. The aim of the trial is to compare sequential addition of\n      insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects\n      with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and\n      metformin and in need of further intensification.\n\n      This is an extension to trial NN9068-3952, NCT01952145 (DUAL\u2122 V)."
        }, 
        "brief_title": "A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completion (Visit 28) of NN9068-3952 with insulin degludec/liraglutide + metformin\n\n          -  HbA1c (glycosylated haemoglobin) above or equal to 7 percent at Visit 27 of\n             NN9068-3952 trial\n\n        Exclusion Criteria:\n\n          -  Clinically significant diseases of the major organ systems\n\n          -  Screening calcitonin above or equal to 50 ng/L"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100475", 
            "org_study_id": "NN9068-4119", 
            "secondary_id": [
                "2013-002878-47", 
                "U1111-1145-0183"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin degludec/liraglutide + Metformin", 
                "description": "Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.\nDose individually adjusted.", 
                "intervention_name": "insulin degludec/liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin degludec/liraglutide + Insulin Aspart + Metformin", 
                "description": "Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.\nDose individually adjusted.", 
                "intervention_name": "insulin degludec/liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin degludec/liraglutide + Insulin Aspart + Metformin", 
                "description": "Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin", 
                "Metformin", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 8, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93720"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40503"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Slidell", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70461-4231"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tipton", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16684"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Renton", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98057"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Capital Federal", 
                        "country": "Argentina", 
                        "zip": "C1056ABJ"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wollongong", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2500"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "GR-11527"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eger", 
                        "country": "Hungary", 
                        "zip": "3300"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pachuca", 
                        "country": "Mexico", 
                        "state": "Hidalgo", 
                        "zip": "42060"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tomsk", 
                        "country": "Russian Federation", 
                        "zip": "634034"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Trnava", 
                        "country": "Slovakia", 
                        "zip": "91701"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alberton", 
                        "country": "South Africa", 
                        "zip": "1449"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Australia", 
                "Greece", 
                "Hungary", 
                "Mexico", 
                "Russian Federation", 
                "Slovakia", 
                "South Africa", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL\u2122 - Intensification)", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Greece: National Organization of Medicines", 
                "Hungary: Ministry of Health, Social and Family Affairs", 
                "Mexico: National Institute of Public Health, Health Secretariat", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Slovakia: State Institute for Drug Control", 
                "Spain: Spanish Agency of Medicines", 
                "South Africa: Medicines Control Council", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in HbA1c (glycosylated haemoglobin)", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100475"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in body weight", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 26"
            }, 
            {
                "measure": "Number of treatment-emergent confirmed hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Week 0 - 26"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}